216 related articles for article (PubMed ID: 10561359)
1. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.
Lee EJ; George SL; Caligiuri M; Szatrowski TP; Powell BL; Lemke S; Dodge RK; Smith R; Baer M; Schiffer CA
J Clin Oncol; 1999 Sep; 17(9):2831-9. PubMed ID: 10561359
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
Kolitz JE; George SL; Dodge RK; Hurd DD; Powell BL; Allen SL; Velez-Garcia E; Moore JO; Shea TC; Hoke E; Caligiuri MA; Vardiman JW; Bloomfield CD; Larson RA;
J Clin Oncol; 2004 Nov; 22(21):4290-301. PubMed ID: 15514371
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
Baer MR; George SL; Dodge RK; O'Loughlin KL; Minderman H; Caligiuri MA; Anastasi J; Powell BL; Kolitz JE; Schiffer CA; Bloomfield CD; Larson RA
Blood; 2002 Aug; 100(4):1224-32. PubMed ID: 12149202
[TBL] [Abstract][Full Text] [Related]
4. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
Sonneveld P; Burnett A; Vossebeld P; Ben-Am M; Rosenkranz G; Pfister C; Verhoef G; Dekker A; Ossenkoppele G; Ferrant C; Yin L; Gratwohl A; Kovacsovics T; Vellenga E; Capdeville R; Löwenberg B
Hematol J; 2000; 1(6):411-21. PubMed ID: 11920222
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
Dorr R; Karanes C; Spier C; Grogan T; Greer J; Moore J; Weinberger B; Schiller G; Pearce T; Litchman M; Dalton W; Roe D; List AF
J Clin Oncol; 2001 Mar; 19(6):1589-99. PubMed ID: 11250987
[TBL] [Abstract][Full Text] [Related]
6. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
[TBL] [Abstract][Full Text] [Related]
7. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
Visani G; Milligan D; Leoni F; Chang J; Kelsey S; Marcus R; Powles R; Schey S; Covelli A; Isidori A; Litchman M; Piccaluga PP; Mayer H; Malagola M; Pfister C
Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
List AF; Spier C; Greer J; Wolff S; Hutter J; Dorr R; Salmon S; Futscher B; Baier M; Dalton W
J Clin Oncol; 1993 Sep; 11(9):1652-60. PubMed ID: 8102639
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.
Bauer KS; Karp JE; Garimella TS; Wu S; Tan M; Ross DD
Leuk Res; 2005 Mar; 29(3):263-71. PubMed ID: 15661261
[TBL] [Abstract][Full Text] [Related]
10. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
Bishop JF; Matthews JP; Young GA; Szer J; Gillett A; Joshua D; Bradstock K; Enno A; Wolf MM; Fox R; Cobcroft R; Herrmann R; Van Der Weyden M; Lowenthal RM; Page F; Garson OM; Juneja S
Blood; 1996 Mar; 87(5):1710-7. PubMed ID: 8634416
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
Kolitz JE; George SL; Marcucci G; Vij R; Powell BL; Allen SL; DeAngelo DJ; Shea TC; Stock W; Baer MR; Hars V; Maharry K; Hoke E; Vardiman JW; Bloomfield CD; Larson RA;
Blood; 2010 Sep; 116(9):1413-21. PubMed ID: 20522709
[TBL] [Abstract][Full Text] [Related]
12. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.
Chauncey TR; Rankin C; Anderson JE; Chen I; Kopecky KJ; Godwin JE; Kalaycio ME; Moore DF; Shurafa MS; Petersdorf SH; Kraut EH; Leith CP; Head DR; Luthardt FW; Willman CL; Appelbaum FR
Leuk Res; 2000 Jul; 24(7):567-74. PubMed ID: 10867130
[TBL] [Abstract][Full Text] [Related]
14. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
Gruber A; Björkholm M; Brinch L; Evensen S; Gustavsson B; Hedenus M; Juliusson G; Löfvenberg E; Nesthus I; Simonsson B; Sjo M; Stenke L; Tangen JM; Tidefelt U; Udén AM; Paul C; Liliemark J
Leuk Res; 2003 Apr; 27(4):323-8. PubMed ID: 12531223
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
Advani R; Saba HI; Tallman MS; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Sikic BI; Greenberg PL
Blood; 1999 Feb; 93(3):787-95. PubMed ID: 9920827
[TBL] [Abstract][Full Text] [Related]
17. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.
Anderson JE; Kopecky KJ; Willman CL; Head D; O'Donnell MR; Luthardt FW; Norwood TH; Chen IM; Balcerzak SP; Johnson DB; Appelbaum FR
Blood; 2002 Dec; 100(12):3869-76. PubMed ID: 12393614
[TBL] [Abstract][Full Text] [Related]
18. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
19. The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy.
Friedenberg WR; Miller HJ; Marx JJ; Schloesser LL; Reding DJ; Mazza JJ; Hocking WG; Mercier RJ; Raich PC; Cassileth PA
Am J Clin Oncol; 1995 Apr; 18(2):105-10. PubMed ID: 7900701
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
